Citadel Advisors
NRIX icon

Citadel Advisors’s Nurix Therapeutics NRIX Stock Holding History

Citadel Advisors’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.8M Buy
1,477,019
+133,319
+10% +$2.27M ﹤0.01% 1903
2026
Q1 		$20.8M Buy
1,343,700
+190,770
+17% +$3.16M ﹤0.01% 2295
2025
Q4 		$21.9M Buy
1,152,930
+587,625
+104% +$8.44M ﹤0.01% 2248
2025
Q3 		$5.22M Sell
565,305
-1,023,730
-64% -$10.6M ﹤0.01% 4285
2025
Q2 		$18.1M Buy
1,589,035
+271,577
+21% +$2.93M ﹤0.01% 2269
2025
Q1 		$15.7M Buy
1,317,458
+465,939
+55% +$7.79M ﹤0.01% 2315
2024
Q4 		$16M Sell
851,519
-679,686
-44% -$15.6M ﹤0.01% 2410
2024
Q3 		$34.4M Buy
1,531,205
+490,539
+47% +$11.1M 0.01% 1546
2024
Q2 		$21.7M Buy
1,040,666
+825,950
+385% +$12.9M ﹤0.01% 1916
2024
Q1 		$3.16M Buy
214,716
+182,847
+574% +$1.97M ﹤0.01% 4688
2023
Q4 		$329K Sell
31,869
-36,599
-53% -$251K ﹤0.01% 8986
2023
Q3 		$538K Buy
68,468
+53,002
+343% +$484K ﹤0.01% 7900
2023
Q2 		$155K Sell
15,466
-41,024
-73% -$418K ﹤0.01% 10297
2023
Q1 		$502K Sell
56,490
-62,717
-53% -$654K ﹤0.01% 8303
2022
Q4 		$1.31M Sell
119,207
-19,472
-14% -$235K ﹤0.01% 6300
2022
Q3 		$1.81M Buy
+138,679
New +$2.19M ﹤0.01% 5783
2022
Q2 		– Sell
-211,783
Closed -$2.4M – 13712
2022
Q1 		$2.97M Buy
211,783
+158,504
+297% +$2.81M ﹤0.01% 5212
2021
Q4 		$1.54M Buy
53,279
+7,973
+18% +$242K ﹤0.01% 6828
2021
Q3 		$1.36M Sell
45,306
-5,365
-11% -$166K ﹤0.01% 7357
2021
Q2 		$1.34M Buy
+50,671
New +$1.49M ﹤0.01% 7576
2021
Q1 		– Sell
-9,184
Closed -$302K – 13544
2020
Q4 		$302K Sell
9,184
-236,016
-96% -$7.82M ﹤0.01% 9065
2020
Q3 		$8.56M Buy
+245,200
New +$6.18M ﹤0.01% 2472

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors's NRIX Position: Q2 2026 in Review

Citadel Advisors increased its Nurix Therapeutics (NRIX) stake by 9.9% in Q2 2026, buying an estimated $2.27M and bringing the position to 1,477,019 shares worth $35.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1903.

Citadel Advisors first reported a position in NRIX in Q3 2020 and has held it in 22 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • Citadel Advisors held 1,477,019 shares of Nurix Therapeutics worth $35.8M as of Q2 2026.
  • Citadel Advisors bought 133,319 Nurix Therapeutics shares in Q2 2026, an estimated $2.27M.
  • Nurix Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #1903 holding.
  • Citadel Advisors first reported a position in Nurix Therapeutics in Q3 2020 and has held it in 22 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.